Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AbbVie (NY:ABBV)

184.02 +2.34 (+1.29%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?
Via The Motley Fool
Topics Earnings Economy Government
Exposures Financial Political Supply Chain
Invest in These ETFs to Prepare Your Portfolio for a Recession
Being prepared is important 
Via The Motley Fool
Topics ETFs Economy
Exposures Economy
Benzinga Bulls And Bears: Lilly, Microsoft, Starbucks — And Markets Fully Recover Tariff Chaos Losses
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities. 
Via MarketBeat
Topics Economy World Trade
Exposures COVID-19 Supply Chain Tariff
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Netflix, Sherwin-Williams, AbbVie And More On CNBC's 'Final Trades'
Via Benzinga
AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis
AbbVie wins FDA approval for Rinvoq in giant cell arteritis after strong Phase 3 results and a 57.2% year-over-year sales increase in Q1. 
Via Benzinga
Exposures Product Safety
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next?
Shares of AbbVie (ABBV) have gained more than 12% in the past week. But now they are overbought and may reverse. 
Via Benzinga
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this... 
Via Benzinga
United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Topics Government World Trade
Exposures Political Tariff
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
Why AbbVie Stock Trounced the Market Today
Via The Motley Fool
These S&P500 stocks are moving in today's session
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst
Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments. 
Via Benzinga
Exploring the top movers within the S&P500 index during today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
Exposures COVID-19
US Stock Futures Fall As Markets Brace For Earnings From Microsoft, Meta, Apple And Apple This Week: 'Earnings Estimates Don't Signal A Recession' Says Leading Analyst
U.S. stock futures are down in early-morning trade on Monday, after ending the previous week on a high note, with back-to-back sessions of strong rallies. 
Via Benzinga
Should Investors Be Worried About Dividend King AbbVie?
Via The Motley Fool
Topics Earnings Government World Trade
Exposures Financial Political Tariff
Incyte (INCY) Q1 Earnings Report Preview: What To Look For
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results tomorrow morning. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Government World Trade
Exposures Artificial Intelligence Political Tariff
Regeneron (REGN) Reports Earnings Tomorrow: What To Expect
Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know. 
Via StockStory
Topics World Trade
Exposures Tariff
Market Monitor April 28 ( Alphabet, Nvidia & Meta UP, Intel DOWN)
US Markets Rise as Big Tech Shines, Trade Tensions Remain a Concern 
Via Chartmill
Topics World Trade
Exposures Tariff
AbbVie Stock: Q1 Earnings Beat and EPS Outlook Raised
Despite some near-term pressures in aesthetics and legacy products, the overall outlook for 2025 remains positive. 
Via Talk Markets
Topics Earnings Stocks / Equities
Exposures Financial
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Economy Intellectual Property World Trade
Exposures Economy Intellectual Property Tariff
How Much Would It Take To Earn $100 A Month From AbbVie Stock
Via Benzinga
Why AbbVie Stock Topped the Market Today
Via The Motley Fool
Topics Earnings
Exposures Financial
Wall Street Rally Pauses, Tesla Heads For Strongest Week In 6 Months: What's Driving Markets Friday?
Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on U.S.-China trade relations. 
Via Benzinga
AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector
AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience portfolios led the results. 
Via Benzinga
Topics Earnings
Exposures Financial
Get insights into the top movers in the S&P500 index of Friday's pre-market session.
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.